Funds to support innovation and answers in WA state research institutions Sept. 21, 2023 For Immediate Release Molly O’Connor, CEO(206) 490-0878; molly.oconnor@rivkin.org SEATTLE – Washington state ovarian cancer researchers will have an extra $1M in grant funding over the next two years thanks to a pioneering public-private partnership between the Rivkin Center for Ovarian Cancer […]
Read More
To say that a cure for ovarian cancer, or any cancer for that matter, is the “holy grail” of cancer research is like saying the sky is blue. We all know a cure is the goal. If a cure is the goal, then improved detection, new prevention methods, and new treatments are the low-hanging fruit. […]
Read More
The Rivkin Center is proud to announce that we have awarded $810,000 in ovarian cancer research grants to nine scientists across the globe.
Read More
We’re excited to share results of three recent studies that provide hope for women with newly diagnosed ovarian cancer. The studies, reported at the annual meeting of the European Society of Medical Oncology and two of which were published in the New England Journal of Medicine recently, show that three different types of PARP inhibitors […]
Read More
The Federal Drug Administration (FDA) made an exciting announcement this week with the first approval for PARP inhibitors to be used for patients following their initial diagnosis and treatment to reduce the risk of recurrence. The FDA approved the use of the PARP inhibitor olaparib (Lynparza®) for frontline maintenance therapy for advanced epithelial ovarian, fallopian […]
Read More
You may have read in recent news that a new research study found that daily, low-dose aspirin may lower a woman’s risk of developing ovarian cancer. So does that mean you should start — or change — your aspirin regimen? Dr. Nora Disis, our Medical and Scientific Director and the Director of the University of […]
Read More
PARP inhibitors represent an important new class of anticancer agents that are having a major impact on ovarian cancer treatment. These drugs target vulnerabilities in DNA damage response and repair pathways especially in cancer cells that have defects in BRCA and related genes. In an important clinical development announced April 6, 2018, the FDA expanded […]
Read More
Report: New blood test for early detection of 8 major cancer types What does this mean for you? You may have heard the recent hype about a new study in which a blood test was used for the early detection of 8 major cancer types. What does the study really mean and, more importantly, when […]
Read MoreA study published in Lancet Oncology by Dr. Iain McNeish (2016 Rivkin Pilot Award Recipient), Dr. Elizabeth Swisher (2009 Rivkin Pilot Award Recipient), and colleagues provided key data that helped fuel the FDA’s recent approval of rucaparib for ovarian cancers with defects in the BRCA1 and BRCA2 genes in women previously treated with two or more chemotherapies.
Read More
This week, the Rivkin Center extended a special invitation to a very select group of ovarian cancer researchers to apply for a major new Rivkin research grant. This is a big departure from our typical funding model.
Read More